

Haematologica
HAEMATOL/2018/210146
Version 3

Rapid growth is a dominant predictor of hepcidin suppression and declining ferritin in Gambian infants

Andrew E. Armitage, Schadrac C. Agbla, Modupeh Betts, Ebrima A. Sise, Momodou W. Jallow, Ellen Sambou, Bakary Darboe, Archibald Worwui, George M. Weinstock, Martin Antonio, Sant-Rayn Pasricha, Andrew M. Prentice, Hal Drakesmith, Momodou K. Darboe, and Brenda Anna Kwambana-Adams

Disclosures: The original VA study was funded by the UK Medical Research Council (MRC) (see below). The original VPM study was funded by the Bill & Melinda Gates Foundation (BMGF). The current analyses were supported by BMGF (OPP 1055865) awarded to the MRC International Nutrition Group which is core-funded by MCA760-5QX00 from the MRC and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement. AEA and HD receive core-funding through the MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford (MC_UU_12010/3). HD reports research support from Pfizer, Vifor and LJPC and a consultancy with Alnylam. No other authors have a conflict of interest to disclose.

Contributions: AEA: Conceived the study and its analysis, analyzed and interpreted data, wrote the manuscript SCA: Performed statistical analyses and interpreted data, prepared manuscript MB, EAS, MWJ, ES, BD: Performed field and laboratory analyses AW: Managed data collection and cleaning for the VPM study SRP, GMW, MA, AMP, HD: Conceived the study, obtained funding, interpreted data, provided critical feedback on manuscript MKD: Led and coordinated the VA study, BAKA: Conceived the present study; led and coordinated the VPM study; analyzed and interpreted data, wrote the manuscript All authors approved the final version of the manuscript